Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $708.73M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.21M
Average 1.39M
SLDB Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Solid Biosciences Inc.NASDAQ: SLDB
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $47.4M (cash outflow) rose 48.2% year over year, behind the +61.1% change in trailing-twelve-month free cash flow. Sequentially, it fell 12.4% from the prior quarter. Over 3 fiscal years it compounded at +16.0% a year.
Context
- Free cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +48.2% toward the trailing-twelve-month pace of +61.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (157.44M) USD
- Year-over-year change
- -56.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (157.44M) | -56.4% |
| FY2024 | 2024-12-31 | (100.67M) | -5.2% |
| FY2023 | 2023-12-31 | (95.7M) | +5.2% |
| FY2022 | 2022-12-31 | (100.99M) | -27.8% |
| FY2021 | 2021-12-31 | (79.05M) | — |
Free Cash Flow vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's LTM Mar 2026 free cash flow of $172.86M is the 4th largest of the 10 companies compared; the peer median is $113.96M.
- Its year-over-year change of +61.1% is the 3rd highest of 10, against a peer median of +15.9%.
- Over three fiscal years its annual growth of +16.0% compares with a peer median of +9.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $499.22M | +37.9% | +37.2% | — | |
| LTM Jun 2026 | $332.56M | -148.8% | — | 33.0% | |
| LTM Sep 2026 | $202.02M | +52.3% | +35.2% | — | |
| LTM Mar 2026 | $172.86M | +61.1% | +16.0% | — | |
| LTM Mar 2026 | $130.06M | -17.1% | +3.6% | 147.4% | |
| LTM Mar 2026 | $113.96M | +141.6% | — | — | |
| LTM Mar 2026 | $106.14M | +115.2% | -4.9% | 4.9% | |
| LTM Mar 2026 | $82.61M | +15.9% | +12.5% | — | |
| LTM Mar 2026 | $77.27M | -7.3% | +9.1% | — | |
| LTM Mar 2026 | $2.34M | -97.9% | -24.8% | 2.9% | |
| Peer median (excluding SLDB) | $113.96M | +15.9% | +9.1% | 18.9% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | (1.87M) |
| Deferred Income Tax | 1.21M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.37M | 7.54M | 7.63M | 10.52M | 16.91M |
| Change in Working Capital | (23.04M) | (3.69M) | (6.34M) | 2.85M | (6.82M) |
| Accounts Receivables | (110K) | 110K | 0 | 0 | 0 |
| Inventory | (11.5M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.21M | (5.25M) | (764K) | 2.21M | (1.09M) |
| Other Working Capital | (12.64M) | 1.45M | (5.57M) | 645K | (5.73M) |
| Other Non-Cash Items | (81K) | (18.25M) | (2.03M) | 8.86M | 9.82M |
| Operating Cash Flow | (77.76M) | (97.98M) | (94.18M) | (100.01M) | (156.29M) |
| Capital Expenditures | (1.28M) | (3.02M) | (1.52M) | (654K) | (1.15M) |
| Acquisitions (Net) | 89.81M | 31.52M | 0 | 5K | 85K |
| Purchases of Investments | (141.25M) | (182.76M) | (117.43M) | (204.34M) | (235.89M) |
| Sales of Investments | 51.44M | 212.81M | 128.63M | 188.9M | 178.5M |
| Other Investing Activities | (89.81M) | 600K | 0 | 0 | 0 |
| Investing Cash Flow | (91.09M) | 59.16M | 9.69M | (16.09M) | (58.45M) |
| Debt Repayment | 0 | 2.08M | 0 | (473K) | (723K) |
| Common Stock Issued | 134.88M | 72.55M | 2.97M | 127.23M | 194.74M |
| Common Stock Repurchased | 0 | 0 | 0 | (5.11M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 107K | 203K | 148K | 794K | 425K |
| Financing Cash Flow | 134.99M | 74.83M | 3.12M | 122.44M | 194.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (33.87M) | 36.01M | (81.37M) | 6.34M | (20.3M) |
| Free Cash Flow | (79.05M) | (100.99M) | (95.7M) | (100.67M) | (157.44M) |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.